Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Noy Ariela; de Vos Sven; Thieblemont Catherine; Martin Peter; Flowers Christopher; Morschhauser Franck; Collins Graham P.; Ma Shuo; Coleman Morton; Peles Shachar; Smith Stephen; Smith Alina; Munneke Brian; Dimery Isaiah; Beaupre Darrin; Chen Robert W.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

【24h】

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

机译：单剂依鲁替尼证明复发/难治性边缘区淋巴瘤患者的疗效和安全性：多中心，开放标签，2期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共6页
作者
Noy Ariela; de Vos Sven; Thieblemont Catherine; Martin Peter; Flowers Christopher; Morschhauser Franck; Collins Graham P.; Ma Shuo; Coleman Morton; Peles Shachar; Smith Stephen; Smith Alina; Munneke Brian; Dimery Isaiah; Beaupre Darrin; Chen Robert W.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study [J] . Noy Ariela, de Vos Sven, Thieblemont Catherine, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：单剂依鲁替尼证明复发/难治性边缘区淋巴瘤患者的疗效和安全性：多中心，开放标签，2期研究
2. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J] . Czuczman Myron S., Trneny Marek, Davies Andrew, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第15期

机译：2/3个多中心，随机的开放标签研究，用于比较Lenalidomide对调查患者在复发或难治性弥漫性大B细胞淋巴瘤患者中的疗效和安全性
3. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma [J] . Cassaday Ryan D., Goy Andre, Advani Suresh, Clinical lymphoma, myeloma & leukemia . 2015,第7期

机译：II期，单臂，开放标签，多中心研究，用于评估P276-00（一种细胞周期蛋白依赖性激酶抑制剂）在复发性或难治性套细胞淋巴瘤患者中的疗效和安全性
4. An open-label, multicenter, randomized,comparative, safety, efficacy, cycle control,and quality of life study of CTR 25, Alesse ,and Ortho Tri-Cyclen [C] . Victoria Davis, Brian Hauck, Sheila Dunn, World Congress on Fertility and Sterility . 2004

机译：开放标签，多中心，随机，比较，安全，疗效，循环控制和CTR 25，Alesse和Ortho Tri-Cyclen的生命研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Phase II Single-Arm Open-Label Multicenter Study to Evaluate the Efficacy and Safety of P276-00 a Cyclin Dependent Kinase Inhibitor in Patients with Relapsed or Refractory Mantle Cell Lymphoma [O] . Ryan D. Cassaday, Andre Goy, Suresh Advani, -1

机译：II期单臂开放标签多中心研究用于评估P276-00（一种细胞周期蛋白依赖性激酶抑制剂）在复发性或难治性套细胞淋巴瘤患者中的疗效和安全性
7. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study [O] . Ajay K. Gopal, Stephen J. Schuster, Nathan H. Fowler, 2018

机译：Ibrutinib作为复发/难治性滤泡淋巴瘤患者的治疗：开放标签，多中心，第二阶段黎明研究的结果

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

著录项

相似文献

相关主题

期刊订阅